Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing
Sight Sciences | 10-Q: Quarterly report
Sight Sciences, Inc. (NASDAQ:SGHT) Analysts Are Pretty Bullish On The Stock After Recent Results
Shareholders of Sight Sciences, Inc. (NASDAQ:SGHT) will be pleased this week, given that the stock price is up 13% to US$5.96 following its latest first-quarter results. Revenue of US$19m came i
Earnings Call Summary | Sight Sciences(SGHT.US) Q1 2024 Earnings Conference
The following is a summary of the Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript:Financial Performance:Sight Sciences reported Q1 2024 revenue of $19.3 million, a record for their first
Sight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed
Sight Sciences (SGHT) shares were up nearly 4%, a day after the company reported narrower Q1 loss and revenue that exceeded consensus. The company reported Q1 net loss Thursday of $0.33 per diluted sh
Piper Sandler: Reiterates the Sight Sciences (SGHT.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.
Piper Sandler: Reiterates the Sight Sciences (SGHT.US) rating, adjusted from neutral to neutral, and adjusted the target price from $5.00 to $6.00.
Piper Sandler Reiterates Neutral on Sight Sciences, Raises Price Target to $6
Piper Sandler analyst Matt O'Brien reiterates Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $5 to $6.
Piper Sandler Sticks to Their Hold Rating for Sight Sciences (SGHT)
Needham Remains a Hold on Sight Sciences (SGHT)
Sight Sciences Q1 2024 GAAP EPS $(0.33) Misses $(0.30) Estimate, Sales $19.265M Beat $18.382M Estimate
Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 5.71 percent increase over losses of $(0.35)
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, Vs. Street Est of $18.4M
04:29 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M
Sight Sciences Enhances Transparency With Strategic Financial Moves
Sight Sciences Backs FY24 Rev $81M-$85M >SGHT
Sight Sciences Backs FY24 Rev $81M-$85M >SGHT
Sight Sciences 1Q Loss/Shr 33c >SGHT
Sight Sciences 1Q Loss/Shr 33c >SGHT
Sight Sciences Reaffirms Full Yr 2024 Fincl Guidance
Sight Sciences Reaffirms Full Yr 2024 Fincl Guidance
Press Release: Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("
Sight Sciences Shares Rise 16% on $34M Verdict in Patent Infringement Case
By Denny Jacob Sight Sciences shares rose following a positive jury trial verdict in a patent infringement case. Shares were trading up 16% at $6.13 in recent trading. The stock is up 18% on the yea
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences"), an eyecare technology company focused on developing and commercializing innovative, interventional
With 34% Ownership, Sight Sciences, Inc. (NASDAQ:SGHT) Has Piqued the Interest of Institutional Investors
No Data